bullish
Insights On China Healthcare Policy - 4+7: New Volume-Based Purchasing Policy
447 Views22 Oct 2020 16:00
This article analyzed China’s revolutionary volume-based purchasing policy, its impact on domestic healthcare companies and related investment opportunities resulting from such policy.
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- Tigermed (300347.CN/03347.HK) - Q3 Performance Recovered with Optimistic Future Development05 Nov 2020
- Jiangsu Hengrui Medicine (600276 CH) - Q3 Performance Improved with Promising Innovative Pipeline28 Oct 2020
- China Healthcare Weekly (Oct.23)26 Oct 2020
- A Different Angle - Simcere Pharmaceutical VS Everest Medicines (01952.HK)11 Oct 2020
- Betta Pharmaceuticals (300558.SZ) - The Harvest Season Is Coming07 Oct 2020
- Autonomous Driving- The Tesla Delusion06 Apr 2018
x